93 related articles for article (PubMed ID: 210279)
21. Binding of Clostridium perfringens 125I-labeled delta-toxin to erythrocytes.
Jolivet-Reynaud C; Alouf JE
J Biol Chem; 1983 Feb; 258(3):1871-7. PubMed ID: 6822539
[TBL] [Abstract][Full Text] [Related]
22. Clostridium perfringens epsilon toxin: the third most potent bacterial toxin known.
Alves GG; Machado de Ávila RA; Chávez-Olórtegui CD; Lobato FC
Anaerobe; 2014 Dec; 30():102-7. PubMed ID: 25234332
[TBL] [Abstract][Full Text] [Related]
23. Effect of epsilon toxin-GFP on MDCK cells and renal tubules in vivo.
Soler-Jover A; Blasi J; Gómez de Aranda I; Navarro P; Gibert M; Popoff MR; Martín-Satué M
J Histochem Cytochem; 2004 Jul; 52(7):931-42. PubMed ID: 15208360
[TBL] [Abstract][Full Text] [Related]
24. An assessment of the in vitro toxicology of Clostridium perfringens type D epsilon-toxin in human and animal cells.
Shortt SJ; Titball RW; Lindsay CD
Hum Exp Toxicol; 2000 Feb; 19(2):108-16. PubMed ID: 10773840
[TBL] [Abstract][Full Text] [Related]
25. Comparative toxic effect of the surface lipid of Corynebacterium ovis on peritoneal macrophages.
Hard GC
Infect Immun; 1975 Dec; 12(6):1439-49. PubMed ID: 1205621
[TBL] [Abstract][Full Text] [Related]
26. Selection of a Clostridium perfringens type D epsilon toxin producer via dot-blot test.
Gonçalves LA; Lobato ZI; Silva RO; Salvarani FM; Pires PS; Assis RA; Lobato FC
Arch Microbiol; 2009 Nov; 191(11):847-51. PubMed ID: 19779698
[TBL] [Abstract][Full Text] [Related]
27. Functional and structural characterization of soluble recombinant epsilon toxin of Clostridium perfringens D, causative agent of enterotoxaemia.
Mathur DD; Deshmukh S; Kaushik H; Garg LC
Appl Microbiol Biotechnol; 2010 Oct; 88(4):877-84. PubMed ID: 20676627
[TBL] [Abstract][Full Text] [Related]
28. Clostridium perfringens epsilon-toxin increases permeability of single perfused microvessels of rat mesentery.
Adamson RH; Ly JC; Fernandez-Miyakawa M; Ochi S; Sakurai J; Uzal F; Curry FE
Infect Immun; 2005 Aug; 73(8):4879-87. PubMed ID: 16041001
[TBL] [Abstract][Full Text] [Related]
29. [Characterization of a Cl. Perfringens type D strain, isolated in the field and optimization of epsilon toxin biosynthesis in a cell culture].
Maaroufi A; Metoui W; Rahmouni S; Ghram A
Arch Inst Pasteur Tunis; 2000; 77(1-4):67-72. PubMed ID: 14658231
[TBL] [Abstract][Full Text] [Related]
30. Structural studies on epsilon-prototoxin of Clostridium perfringens type D. Localization of the site of tryptic scission necessary for activation to epsilon-toxin.
Bhown AS; Habeerb AF
Biochem Biophys Res Commun; 1977 Oct; 78(3):889-96. PubMed ID: 199192
[No Abstract] [Full Text] [Related]
31. Potency against enterotoxemia of a recombinant Clostridium perfringens type D epsilon toxoid in ruminants.
Lobato FC; Lima CG; Assis RA; Pires PS; Silva RO; Salvarani FM; Carmo AO; Contigli C; Kalapothakis E
Vaccine; 2010 Aug; 28(38):6125-7. PubMed ID: 20670910
[TBL] [Abstract][Full Text] [Related]
32. Molecular cloning and expression of epsilon toxin from Clostridium perfringens type D and tests of animal immunization.
Souza AM; Reis JK; Assis RA; Horta CC; Siqueira FF; Facchin S; Alvarenga ER; Castro CS; Salvarani FM; Silva RO; Pires PS; Contigli C; Lobato FC; Kalapothakis E
Genet Mol Res; 2010 Feb; 9(1):266-76. PubMed ID: 20198582
[TBL] [Abstract][Full Text] [Related]
33. Ganglioside identification on human monocyte membrane with Clostridium perfringens delta-toxin.
Cavaillon JM; Jolivet-Reynaud C; Fitting C; David B; Alouf JE
J Leukoc Biol; 1986 Jul; 40(1):65-72. PubMed ID: 2872258
[TBL] [Abstract][Full Text] [Related]
34. Isolation and characterization of antibodies to Clostridium perfringens epsilon toxin from hyperimmune horse serum.
Worthington RW; Mülders MS
Onderstepoort J Vet Res; 1979 Sep; 46(3):121-4. PubMed ID: 233148
[TBL] [Abstract][Full Text] [Related]
35. Development of monoclonal antibodies suitable for use in antigen quantification potency tests for clostridial veterinary vaccines.
Hauer PJ; Clough NE
Dev Biol Stand; 1999; 101():85-94. PubMed ID: 10566780
[TBL] [Abstract][Full Text] [Related]
36. Distribution of labeled Clostridium perfringens epsilon toxin in mice.
Nagahama M; Sakurai J
Toxicon; 1991; 29(2):211-7. PubMed ID: 2048139
[TBL] [Abstract][Full Text] [Related]
37. Acute Effect of Pore-Forming
Cases M; Llobet A; Terni B; Gómez de Aranda I; Blanch M; Doohan B; Revill A; Brown AM; Blasi J; Solsona C
eNeuro; 2017; 4(4):. PubMed ID: 28798954
[TBL] [Abstract][Full Text] [Related]
38. Molecular cloning of Clostridium perfringens epsilon-toxin gene and its high level expression in E. coli.
Goswami PP; Rupa P; Prihar NS; Garg LC
Biochem Biophys Res Commun; 1996 Sep; 226(3):735-40. PubMed ID: 8831683
[TBL] [Abstract][Full Text] [Related]
39. Cytotoxin CctA, a major virulence factor of Clostridium chauvoei conferring protective immunity against myonecrosis.
Frey J; Johansson A; Bürki S; Vilei EM; Redhead K
Vaccine; 2012 Aug; 30(37):5500-5. PubMed ID: 22749595
[TBL] [Abstract][Full Text] [Related]
40. Epsilon toxin: a fascinating pore-forming toxin.
Popoff MR
FEBS J; 2011 Dec; 278(23):4602-15. PubMed ID: 21535407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
